Key result
SMART Pass deactivation linked to ~5.4-fold higher risk of inappropriate S-ICD shocks.
Why the study?
The SMART Pass filter reduces inappropriate therapy in S-ICD patients but can deactivate due to low amplitude sensed R waves or asystole. This study evaluated the association between filter deactivation and inappropriate therapy and assessed whether device reprogramming or lead/generator repositioning could reduce this risk.
Cohort (n=348)
No
Answers are grounded in this paper and cite their sources.
Supports preserving SMART Pass activation when feasible; hypothesis-generating for corrective interventions in S-ICD patients.
AIMS: The SMART Pass™ (SP) algorithm is a high-pass filter that aims to reduce inappropriate therapy (IT) in subcutaneous internal cardiac defibrillator (S-ICD), but SP can deactivate due to low amplitude sensed R waves or asystole. The association between IT and SP deactivation and management strategies were evaluated, hypothesizing SP deactivation increases the risk of IT and device re-programming, or lead/generator re-positioning could reduce this risk. METHODS AND RESULTS: Retrospective single-centre audit of Emblem™ S-ICD devices implanted 2016 to 2020 utilizing health records and remote monitoring data. Cox regression models evaluated associations between SP deactivation and IT. A total of 348 patients (27 ± 16.6 months follow-up) were studied: 73% primary prevention. Thirty-eight patients (11.8%) received 83 shocks with 27 patients (7.8%) receiving a total of 44 IT. Causes of IT were oversensing (98%) and aberrantly conducted atrial fibrillation (2%). SP deactivation occurred in 32 of 348 patients (9%) and was significantly associated with increased risk of IT (hazard ratio 5.36, 95% CI 2.37-12.13). SP deactivation was due to low amplitude R waves (94%), associated with a higher defibrillation threshold at implant and presence of arrhythmogenic right ventricular cardiomyopathy. No further IT occurred 16 ± 15.5 months after corrective interventions, with changing the sensing vector being successful in 59% of cases. CONCLUSION: To reduce the risk of IT, the cause of the SP deactivation should be investigated, and appropriate reprogramming, device, or lead modifications made. Utilizing the alert for SP deactivation and electrograms could pro-actively prevent IT.
No takes yet. Share an insight, caveat, or question.
Monkhouse et al. (2023) conducted a cohort in Subcutaneous implantable cardioverter defibrillator (S-ICD) recipients (n=348). SMART Pass (SP) algorithm automatic deactivation (SP OFF) vs. SMART Pass algorithm continuously enabled (SP ON) was evaluated on Inappropriate therapy (IT) (HR 5.36, 95% CI 2.37-12.13, p=<0.001). SMART Pass algorithm deactivation was associated with a significantly increased risk of inappropriate S-ICD therapy (34.4% vs 5.1%; HR 5.36, 95% CI 2.37-12.13, P < 0.001).
Synapse has enriched 10 related papers. Consider them for comparative context: